‘Rapid Adoption’ Expected For US Humira Biosimilars
AmerisourceBergen’s McGowan Also Sees Oncology Biosimilars Capturing Record Market Share
Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.
